Skip to main content
Premium Trial:

Request an Annual Quote

DARPA Awards Genelabs $13.6 Million Biological Toxins Research Grant

Premium

REDWOOD CITY, Calif.--The Defense Advanced Research Projects Agency (DARPA) awarded Genelabs Technologies here a three-year $13.6 million research grant to apply patented technologies to the discovery of small molecule drugs to block pathogens that might be used as biological warfare weapons.

Genelabs' proprietary high-throughput assay system enables the discovery and characterization of molecules that bind to DNA via the screening of combinatorial chemistry libraries. Information derived from the system allows the rational design of compounds that function by binding to specific DNA sequences to regulate gene expression.

Sister technology enables discovery of molecules that bind to double-stranded RNA and has the potential to enable the construction of drugs targeted specifically to RNA viruses, another class of biological warfare agents.

"DARPA is investing in innovative technologies that have the potential to provide significant advances in developing broad countermeasures to biological agents," Program Director Shaun Jones stated.

Filed under

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.